Showing results (271-280 of 296) with videos related to

Sort By:
Pageof 30
Gastroenterology|August 28, 2016
Effectiveness of Ledipasvir-Sofosbuvir Combination in Patients With Hepatitis C Virus Infection and Factors Associated With Sustained Virologic ResponseNorah A Terrault, Stefan Zeuzem, Adrian M Di Bisceglie, et al.
Journal of Hepatology|April 4, 2020
DAA therapy and long-term hepatic function in advanced/decompensated cirrhosis: Real-world experience from HCV-TARGET cohortElizabeth C Verna, Giuseppe Morelli, Norah A Terrault, et al.
Hepatology (Baltimore, Md.)|December 6, 2019
A Randomized Controlled Trial of an Integrated Alcohol Reduction Intervention in Patients With Hepatitis C InfectionRae Jean Proeschold-Bell, Donna M Evon, Jia Yao, et al.
Journal of Hepatology|May 17, 2019
Patient-reported symptoms during and after direct-acting antiviral therapies for chronic hepatitis C: The PROP UP studyDonna M Evon, Souvik Sarkar, Jipcy Amador, et al.
Gut|July 16, 2016
Effectiveness and safety of sofosbuvir plus ribavirin for the treatment of HCV genotype 2 infection: results of the real-world, clinical practice HCV-TARGET studyTania M Welzel, David R Nelson, Giuseppe Morelli, et al.
Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society|November 1, 2015
Interferon-free therapy for genotype 1 hepatitis C in liver transplant recipients: Real-world experience from the hepatitis C therapeutic registry and research networkRobert S Brown, Jacqueline G O'Leary, K Rajender Reddy, et al.
Journal of General Internal Medicine|October 30, 2019
Medication Non-adherence in a Prospective, Multi-center Cohort Treated with Hepatitis C Direct-Acting AntiviralsMarina Serper, Donna M Evon, Paul W Stewart, et al.
Journal of Hepatology|May 23, 2021
Linkage of resistance-associated substitutions in GT1 sofosbuvir + NS5A inhibitor failures treated with glecaprevir/pibrentasvirGary P Wang, Gretja L Schnell, Jens J Kort, et al.
Hepatology (Baltimore, Md.)|May 16, 2017
Safety and efficacy of current direct-acting antiviral regimens in kidney and liver transplant recipients with hepatitis C: Results from the HCV-TARGET studyVarun Saxena, Vandana Khungar, Elizabeth C Verna, et al.
Gastroenterology|November 5, 2013
Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: a phase IIb trialStefan Zeuzem, Thomas Berg, Edward Gane, et al.
Pageof 30